For your patients

The following resources are designed to help your patients learn more about alpha-1.

Downloadable Alpha-1 Foundation Resources

The following tools from the Alpha-1 Foundation help people with alpha-1.

Video resources

Learn more about the PROLASTIN DIRECT program's comprehensive, personalized alpha-1 support for patients and physicians and their practices.



 
 

Show your patients the effects of AAT deficiency (alpha-1).
Watch the MOA video>


Patient Support Organizations

Please refer your patients to these organizations for additional information about alpha-1.

AlphaNet >
AlphaNet has 1 mission—to improve the lives of individuals affected by Alpha-1 Antitrypsin Deficiency. As a not-for-profit organization that is governed by, employs, and serves Alphas, AlphaNet is uniquely able to develop and offer programs and services based on a very personal understanding of how Alpha-1 affects the lives of Alphas. In keeping with this mission, AlphaNet provides a wide range of specialized programs and services designed to meet the specific needs of the Alphas it serves.

Alpha-1 Foundation >
The Alpha-1 Foundation is the only national organization dedicated to developing a cure for alpha-1 and to improving the quality of life for patients and their families. Acting as a patient advocate, the foundation helps the alpha-1 community better connect to one another—strengthening the support and care networks they need.


You will need Adobe® Reader® installed on your computer to view PDFs. You can download a copy of Adobe Reader by clicking the link below.

Get Adobe Reader

Adobe and Adobe Reader are registered trademarks of Adobe Systems Incorporated.


PROLASTIN®-C LIQUID is an alpha1-proteinase inhibitor (human) (alpha1-PI) indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of alpha1-PI (alpha1-antitrypsin deficiency).

Limitations of Use


  • The effect of augmentation therapy with any alpha1-PI, including PROLASTIN-C LIQUID, on pulmonary exacerbations and on the progression of emphysema in alpha1-PI deficiency has not been conclusively demonstrated in randomized, controlled clinical trial
  • Clinical data demonstrating the long-term effects of chronic augmentation or maintenance therapy with PROLASTIN-C LIQUID are not available
  • PROLASTIN-C LIQUID is not indicated as therapy for lung disease in patients in whom severe alpha1-PI deficiency has not been established

PROLASTIN-C LIQUID is contraindicated in immunoglobulin A (IgA)-deficient patients with antibodies against IgA or patients with a history of anaphylaxis or other severe systemic reaction to alpha1-PI products.

Hypersensitivity reactions, including anaphylaxis, may occur. Monitor vital signs and observe the patient carefully throughout the infusion. If hypersensitivity symptoms occur, promptly stop PROLASTIN-C LIQUID infusion and begin appropriate therapy.

Because PROLASTIN-C LIQUID is made from human plasma, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. This also applies to unknown or emerging viruses and other pathogens.

The most common adverse reactions during PROLASTIN-C LIQUID clinical trials in >5% of subjects were diarrhea and fatigue, each of which occurred in 2 subjects (6%).

Please see full Prescribing Information for PROLASTIN-C LIQUID.


References

  1. Data on file, Grifols.
  2. Campos MA, Wanner A, Zhang G, Sandhaus RA. Trends in the diagnosis of symptomatic patients with α1-antitrypsin deficiency between 1968 and 2003. Chest. 2005;128(3):1179-1186.